Preventing Alzheimer's disease by targeting vascular risk factors: Hope and gap

Journal of Alzheimer's Disease

Volumn 32, Issue 3, 2012, Pages 721-731

  Qiu, Chengxuan ^a,b  

^a STOCKHOLM UNIVERSITY   (Sweden)

^b JINING MEDICAL UNIVERSITY   (China)

Author keywords

Alzheimer's disease; cerebrovascular disease; epidemiology; neurodegeneration; prevention; randomized controlled trials; vascular risk factors

Indexed keywords

ANTIHYPERTENSIVE AGENT; CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ALCOHOL CONSUMPTION; ALZHEIMER DISEASE; ANTIHYPERTENSIVE THERAPY; ATHEROSCLEROSIS; DIABETES MELLITUS; HYPERTENSION; IMMOBILIZATION; INFLAMMATION; LIFESTYLE; METABOLIC SYNDROME X; NUTRIENT; OBESITY; PRIMARY PREVENTION; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SMOKING;

EID: 84872238424     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-2012-120922     Document Type: Review

References (92)

1. Reitz C, Brayne C, Mayeux R (2011) Epidemiology of alzheimer disease. Nat Rev Neurol 7, 137-152.
2. Viswanathan A, Rocca WA, Tzourio C (2009) Vascular risk factors and dementia: How to move forward? Neurology 72, 368-374.
3. Barnes DE, Yaffe K (2011) The projected effect of risk factor reduction on alzheimer's disease prevalence. Lancet Neurol 10, 819-828.
4. Qiu C, XuW, Fratiglioni L (2010) Vascular and psychosocial factors for alzheimer's disease: Epidemiological evidence toward intervention. J Alzheimers Dis 20, 689-697.
5. Rusanen M, Kivipelto M, Quesenberry CP Jr, Zhou J, Whitmer RA (2011) Heavy smoking in midlife and long-Term risk of alzheimer disease and vascular dementia. Arch Intern Med 171, 333-339.
6. Anstey KJ, von Sanden C, Salim A, O'Kearney R (2007) Smoking as a risk factor for dementia and cognitive decline: A meta-Analysis of prospective studies. Am J Epidemiol 166, 367-378. (Pubitemid 47216800)
7. Peters R, Poulter R, Warner J, Beckett N, Burch L, Bulpitt C (2008) Smoking, dementia and cognitive decline in the elderly: A systematic review. BMC Geriatr 8, 36.
8. Cataldo JK, Prochaska JJ, Glantz SA (2010) Cigarette smoking is a risk factor for alzheimer's disease: An analysis controlling for tobacco industry affiliation. J Alzheimers Dis 19, 465-480.
9. Anttila T, Helkala EL, Viitanen M, Koareholt I, Fratiglioni L, Winblad B, Soininen H, Tuomilehto J, Nissinen A, Kivipelto M (2004) Alcohol drinking in middle age and subsequent risk of mild cognitive impairment and dementia in old age: A prospective population based study. BMJ 329, 539.
10. Peters R, Peters J, Warner J, Beckett N, Bulpitt C (2008) Alcohol, dementia and cognitive decline in the elderly: A systematic review. Age Ageing 37, 505-512.
11. Anstey KJ, Mack HA, Cherbuin N (2009) Alcohol consumption as a risk factor for dementia and cognitive decline: Meta-Analysis of prospective studies.AmJ Geriatr Psychiatry 17, 542-555.
12. Scarmeas N, Luchsinger JA, Schupf N, Brickman AM, Cosentino S, Tang MX, Stern Y (2009) Physical activity, diet, and risk of alzheimer disease. JAMA 302, 627-637.
13. Hamer M, Chida Y (2009) Physical activity and risk of neurodegenerative disease: A systematic review of prospective evidence. Psychol Med 39, 3-11.
14. F'eart C, Samieri C, RondeauV, Amieva H, Portet F, Dartigues JF, Scarmeas N, Barberger-Gateau P (2009) Adherence to a Mediterranean diet, cognitive decline, and risk of dementia. JAMA 302, 638-648.
15. Gu Y, Luchsinger JA, Stern Y, Scarmeas N (2010) Mediterranean diet, inflammatory and metabolic biomarkers, and risk of alzheimer's disease. J Alzheimers Dis 22, 483-492.
16. Gu Y, Nieves JW, Stern Y, Luchsinger JA, Scarmeas N (2010) Food combination and alzheimer disease risk: A protective diet. Arch Neurol 67, 699-706.
17. Barberger-Gateau P, Raffaitin C, Letenneur L, Berr C, Tzourio C, Dartigues JF, Alp'erovitch A (2007) Dietary patterns and risk of dementia: The Three-City cohort study. Neurology 69, 1921-1930. (Pubitemid 350100350)
18. Fotuhi M, Mohassel P, Yaffe K (2009) Fish consumption, long-chain omega-3 fatty acids and risk of cognitive decline or alzheimer disease: A complex association. Nat Clin Pract Neurol 5, 140-152.
19. Devore EE, Grodstein F, van Rooij FJ, Hofman A, Rosner B, Stampfer MJ, Witteman JC, Breteler MM (2009) Dietary intake of fish and omega-3 fatty acids in relation to long-Term dementia risk. Am J Clin Nutr 90, 170-176.
20. Fratiglioni L, Mangialasche F, Qiu C (2010) Brain aging: Lessons from community studies. Nutr Rev 68(Suppl 2), S119-S127.
21. Dangour AD, Whitehouse PJ, Rafferty K, Mitchell SA, Smith L, Hawkesworth S, Vellas B (2010) B-Vitamins and fatty acids in the prevention and treatment of alzheimer's disease and dementia: A systematic review. J Alzheimers Dis 22, 205-224.
22. Daviglus ML, Plassman BL, Pirzada A, Bell CC, Bowen PE, Burke JR, Connolly ES Jr, Dunbar-Jacob JM, Granieri EC, McGarry K, Patel D, Trevisan M, Williams JW Jr (2011) Risk factors and preventive interventions for alzheimer disease: State of the science. Arch Neurol 68, 11851190.
23. van Dam F, van Gool WA (2009) Hyperhomocysteinemia and alzheimer's disease: A systematic review. Arch Gerontol Geriatr 48, 425-430.
24. Launer LJ, Hughes T, Yu B, Masaki K, Petrovitch H, Ross GW, White LR (2010) Lowering midlife levels of systolic blood pressure as a public health strategy to reduce late-Life dementia: Perspective from the Honolulu Heart Program/Honolulu Asia Aging Study. Hypertension 55, 13521359.
25. Qiu C, Winblad B, Fratiglioni L (2005) The age-Dependent relation of blood pressure to cognitive function and dementia. Lancet Neurol 4, 487-499. (Pubitemid 40982459)
26. Qiu C,Winblad B, Fratiglioni L (2009) Lowdiastolic pressure and risk of dementia in very old people: A longitudinal study. Dement Geriatr Cogn Disord 28, 213-219.
27. Guan JW, Huang CQ, Li YH,Wan CM, You C,Wang ZR, Liu YY, Liu QX (2011) No association between hypertension and risk for alzheimer's disease: A meta-Analysis of longitudinal studies. J Alzheimers Dis 27, 799-807.
28. Power MC, Weuve J, Gagne JJ, McQueen MB, Viswanathan A, Blacker D (2011) The association between blood pressure and incident alzheimer disease:Asystematic reviewand meta-Analysis. Epidemiology 22, 646-659.
29. Duron E, Hanon O (2010) Antihypertensive treatments, cognitive decline, and dementia. J Alzheimers Dis 20, 903-914.
30. Haag MD, Hofman A, Koudstaal PJ, Breteler MM, Stricker BH (2009) Duration of antihypertensive drug use and risk of dementia: A prospective cohort study. Neurology 72, 17271734.
31. Li NC, Lee A, Whitmer RA, Kivipelto M, Lawler E, Kazis LE, Wolozin B (2010) Use of angiotensin receptor blockers and risk of dementia in a predominantly male population: Prospective cohort analysis. BMJ 340, b5465.
32. Beydoun MA, LhotskyA,WangY, Dal Forno G, AnY, Metter EJ, Ferrucci L, O'Brien R, ZondermanAB(2008) Association of adiposity status and changes in early to mid-Adulthood with incidence of alzheimer's disease. Am J Epidemiol 168, 11791189.
33. Fitzpatrick AL, Kuller LH, Lopez OL, Diehr P, O'Meara ES, Longstreth WT, Luchsinger JA (2009) Midlife and late-Life obesity and the risk of dementia: The Cardiovascular Health Study. Arch Neurol 66, 336-342.
34. Beydoun MA, Beydoun HA, Wang Y (2008) Obesity and central obesity as risk factors for incident dementia and its subtypes: A systematic review and meta-Analysis. Obes Rev 9, 204-218. (Pubitemid 351550691)
35. Profenno LA, Porsteinsson AP, Faraone SV (2010) Metaanalysis of alzheimer's disease risk with obesity, diabetes, and related disorders. Biol Psychiatry 67, 505-512.
36. Anstey KJ, Cherbuin N, Budge M,Young J (2011) Body mass index in midlife and late-Life as a risk factor for dementia: A meta-Analysis of prospective studies. Obes Rev 12, e426-e437.
37. Anstey KJ, Lipnicki DM, Low LF (2008) Cholesterol as a risk factor for dementia and cognitive decline: A systematic review of prospective studies with meta-Analysis. Am J Geriatr Psychiatry 16, 343-354.
38. Shepardson NE, Shankar GM, Selkoe DJ (2011) Cholesterol level and statin use in alzheimer disease: II. Reviewof human trials and recommendations. Arch Neurol 68, 1385-1392.
39. Haag MD, Hofman A, Koudstaal PJ, Stricker BH, Breteler MM (2009) Statins are associated with a reduced risk of alzheimer disease regardless of lipophilicity: The rotterdam study. J Neurol Neurosurg Psychiatry 80, 13-17.
40. Ancelin ML, Carrìere I, Barberger-Gateau P, Auriacombe S, Rouaud O, Fourlanos S, Berr C, Dupuy AM, RitchieK(2012) Lipid lowering agents, cognitive decline, and dementia: The Three-City Study. J Alzheimers Dis 30, 629-637.
41. Kopf D, Frölich L (2009) Risk of incident alzheimer's disease in diabetic patients: A systematic review of prospective trials. J Alzheimers Dis 16, 677-685.
42. Lu FP, Lin KP, Kuo HK (2009) Diabetes and the risk of multi-System aging phenotypes: A systematic review and meta-Analysis. Plos One 4, e4144.
43. XuW, Qiu C, Gatz M, Pedersen NL, Johansson B, Fratiglioni L (2009) Mid- And late-Life diabetes in relation to the risk of dementia: A population-Based twin study. Diabetes 58, 71-77.
44. Raffaitin C, Gin H, Empana JP, Helmer C, Berr C, Tzourio C, Portet F, Dartigues JF, Alp'erovitch A, Barberger-Gateau P (2009) Metabolic syndrome and risk for incident alzheimer's disease or vascular dementia: The Three-City Study. Diabetes Care 32, 169-174.
45. Forti P, Pisacane N, Rietti E, Lucicesare A, OlivelliV, Mariani E, Mecocci P, RavagliaG(2010) Metabolic syndrome and risk of dementia in older adults. J Am Geriatr Soc 58, 487-492.
46. Laurin D, David Curb J, Masaki KH, White LR, Launer LJ (2009) Midlife C-Reactive protein and risk of cognitive decline: A 31-year follow-up. Neurobiol Aging 30, 17241727.
47. Sundelöf J, Kilander L, Helmersson J, Larsson A, Rönnemaa E, Degerman-Gunnarsson M, Basun H, Lannfelt L, Basu S (2009) Systemic inflammation and the risk of alzheimer's disease and dementia: A prospective population-Based study. J Alzheimers Dis 18, 79-87.
48. Qiu C (2011) Epidemiological findings of vascular risk factors in alzheimer's disease: Implications for therapeutic and preventive intervention. Expert Rev Neurother 11, 1593-1607.
49. Swardfager W, Lanct̂ct K, Rothenburg L, Wong A, Cappell J, Herrmann N (2010) A meta-Analysis of cytokines in alzheimer's disease. Biol Psychiatry 68, 930-941.
50. Breitner JC, Haneuse SJ,Walker R, Dublin S, Crane PK, Gray SL, Larson EB (2009) Risk of dementia and AD with prior exposure to NSAIDs in an elderly community-Based cohort. Neurology 72, 1899-1905.
51. Ancelin ML, Carrìere I, Helmer C, Rouaud O, Pasquier F, Berr C, Chaudieu I, RitchieK(2012) Steroid and nonsteroidal anti-inflammatory drugs, cognitive decline, and dementia. Neurobiol Aging 33, 2082-2090.
52. Szekely CA, Zandi PP (2010) Non-Steroidal antiinflammatory drugs and alzheimer's disease: The epidemiological evidence. CNS Neurol Disord 9, 132-139.
53. Guerchet M, Aboyans V, Nubukpo P, Lacroix P, Cl'ement JP, Preux PM (2011) Ankle-Brachial index as a marker of cognitive impairment and dementia in general population: A systematic review. Atherosclerosis 216, 251-257.
54. Newman AB, Fitzpatrick AL, Lopez O, Jackson S, Lyketsos C, JagustW, Ives D, Dekosky ST,Kuller LH (2005) Dementia and alzheimer's disease incidence in relationship to cardiovascular disease in the Cardiovascular Health Study cohort. J Am Geriatr Soc 53, 1101-1107. (Pubitemid 41632508)
55. Qiu C, Xu W, Winblad B, Fratiglioni L (2010) Vascular risk profiles for dementia and alzheimer's disease in very old people: A population-Based longitudinal study. J Alzheimers Dis 20, 293-300.
56. Barnes DE, Covinsky K,Whitmer RA, Kuller LH, Lopez OL, YaffeK(2009) Predicting risk of dementia in older adults: The late-Life dementia risk index. Neurology 73, 173-179.
57. Reitz C, Tang MX, Schupf N, Manly JJ, Mayeux R, Luchsinger JA(2010)Asummary risk score for the prediction of alzheimer disease in elderly persons. Arch Neurol 67, 835841.
58. Monastero R, Palmer K, Qiu C, Winblad B, Fratiglioni L (2007) Heterogeneity in risk factors for cognitive impairment, no dementia: Population-Based longitudinal study from the Kungsholmen Project. Am J Geriatr Psychiatry 15, 60-69. (Pubitemid 46106091)
59. Song X, Mitnitski A, Rockwood K (2011) Nontraditional risk factors combine to predict alzheimer disease and dementia. Neurology 77, 227-234.
60. Peters R, Beckett N, Forette F, Tuomilehto J, Clarke R, Ritchie C, Waldman A, Walton I, Poulter R, Ma S, Comsa M, Burch L, Fletcher A, Bulpitt C (2008) Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): A double-Blind, placebo controlled trial. Lancet Neurol 7, 683-689.
61. McGuinness B, Todd S, Passmore P, Bullock R (2009) Blood pressure lowering in patients without prior cerebrovascular disease for prevention of cognitive impairment and dementia. Cochrane Database Syst Rev (4), CD004034.
62. Staessen JA, Thijs L, Richart T, Odili AN, Birkenhäger WH (2011) Placebo-controlled trials of blood pressure-Lowering therapies for primary prevention of dementia. Hypertension 57, e6-e7.
63. McGuinness B, Craig D, Bullock R, Passmore (2009) Statins for the prevention of dementia. Cochrane Database Syst Rev (2), CD003160.
64. Feldman HH, Doody RS, Kivipelto M, Sparks DL, Waters DD, Jones RW, Schwam E, Schindler R, Hey-Hadavi J, DeMicco DA, Breazna A (2010) Randomized controlled trial of atorvastatin in mild to moderate alzheimer disease: LEADe. Neurology 74, 956-964.
65. Sano M, Bell KL, Galasko D, Galvin JE, Thomas RG, van Dyck CH, Aisen PS (2011) A randomized, double-Blind, placebo-controlled trial of simvastatin to treat alzheimer disease. Neurology 77, 556-563.
66. Martin BK, Szekely C, Brandt J, Piantadosi S, Breitner JC, Craft S, Evans D, Green R, MullanM(2008) Cognitive function over time in the alzheimer's disease anti-inflammatory prevention trial (ADAPT): Results of a randomized, controlled trial of naproxen and celecoxib. Arch Neurol 65, 896-905. (Pubitemid 352008472)
67. Jaturapatporn D, Isaac MG, McCleery J, Tabet N (2012) Aspirin, steroidal and non-Steroidal anti-inflammatory drugs for the treatment of alzheimer's disease. Cochrane Database Syst Rev (2), CD006378.
68. Breitner JC, Baker LD, Montine TJ, Meinert CL, Lyketsos CG, Ashe KH, Brandt J, Craft S, Evans DE, Green RC, Ismail MS, Martin BK, Mullan MJ, Sabbagh M, Tariot PN (2011) Extended results of the alzheimer's disease antiinflammatory prevention trial. Alzheimers Dement 7, 402-411.
69. Malouf R, Evans JG (2008) Folic acid with or without vitamin B12 for the prevention and treatment of healthy elderly and demented people. Cochrane Database Syst Rev (4), CD004514.
70. Barkhof F, Polvikoski TM, van Straaten EC, Kalaria RN, Sulkava R, Aronen HJ, Niinistö L, Rastas S, Oinas M, Scheltens P, Erkinjuntti T (2007) The significance of medial temporal lobe atrophy: A postmortem MRI study in the very old. Neurology 69, 1521-1527. (Pubitemid 47537859)
71. Jagust WJ, Zheng L, Harvey DJ, Mack WJ, Vinters HV, Weiner MW, Ellis WG, Zarow C, Mungas D, Reed BR, Kramer JH, Schuff N, DeCarli C, Chui HC (2008) Neuropathological basis of magnetic resonance images in aging and dementia. Ann Neurol 63, 72-80. (Pubitemid 351240553)
72. Scarmeas N, Luchsinger JA, Stern Y, Gu Y, He J, DeCarli C, Brown T, Brickman AM (2011) Mediterranean diet and magnetic resonance imaging-Assessed cerebrovascular disease. Ann Neurol 69, 257-268.
73. de la Torre JC (2005) Is alzheimer's disease preceded by neurodegeneration or cerebral hypoperfusion? Ann Neurol 57, 783-784. (Pubitemid 40798614)
74. Dolan H, Crain B, Troncoso J, Resnick SM, Zonderman AB, Obrien RJ (2010) Atherosclerosis, dementia, and alzheimer's disease in the BLSA cohort. Ann Neurol 68, 231-240.
75. Garcia-Alloza M, Gregory J, Kuchibhotla KV, Fine S, Wei Y, Ayata C, Frosch MP, Greenberg SM, Bacskai BJ (2011) Cerebrovascular lesions induce transient-Amyloid deposition. Brain 134, 3697-3707.
76. Casserly I, Topol E (2004) Convergence of atherosclerosis and alzheimer's disease: Inflammation, cholesterol, and misfolded proteins. Lancet 363, 1139-1146. (Pubitemid 38452789)
77. Strozyk D, Dickson DW, Lipton RB, Katz M, Derby CA, Lee S, Wang C, Verghese J (2010) Contribution of vascular pathology to the clinical expression of dementia. Neurobiol Aging 31, 1710-1720.
78. Debette S, Seshadri S, Beiser A, Au R, Himali JJ, Palumbo C, Wolf PA, DeCarli C (2011) Midlife vascular risk factor exposure accelerates structural brain aging and cognitive decline. Neurology 77, 461-468.
79. Sachdev PS, Chen X,WenW, AnsteyKJ (2008) Light to moderate alcohol use is associated with increased cortical gray matter in middle-Aged men: A voxel-Based morphometric study. Psychiatry Res 163, 61-69.
80. Paul CA, Au R, Fredman L, Massaro JM, Seshadri S, Decarli C, Wolf PA (2008) Association of alcohol consumption with brain volume in the Framingham study. Arch Neurol 65, 13631367.
81. Hafsteinsdottir SH, Eiriksdottir G, Sigurdsson S, Aspelund T, Harris TB, Launer LJ, Gudnason V (2012) Brain tissue volumes by APOE genotype and leisure activity-The AGESReykjavik Study. Neurobiol Aging 33, 829.e1-8.
82. Matsuzaki T, Sasaki K, Tanizaki Y, Hata J, Fujimi K, Matsui Y, Sekita A, Suzuki SO, Kanba S, Kiyohara Y, Iwaki T (2010) Insulin resistance is associated with the pathology of alzheimer disease: The hisayama study. Neurology 75, 764-770.
83. van Elderen SG, de Roos A, de Craen A, Westendorp RG, Blauw GJ, Jukema JW, Bollen EL, Middelkoop HA, van Buchem MA, van der Grond J (2010) Progression of brain atrophy and cognitive decline in diabetes mellitus: A 3-year follow-up. Neurology 75, 997-1002.
84. Kalaria RN (2009) Neurodegenerative disease: Diabetes, microvascular pathology and alzheimer disease. Nat Rev Neurol 5, 305-306.
85. Ahtiluoto S, Polvikoski T, Peltonen M, Solomon A, Tuomilehto J, Winblad B, Sulkava R, Kivipelto M (2010) Diabetes, alzheimer disease, and vascular dementia: A populationbased neuropathologic study. Neurology 75, 1195-1202.
86. Qiu C, Zhang Y, Bronge L, Herlitz A, Aspelin P, Bäckman L, Fratiglioni L,Wahlund LO (2012) Medial temporal lobe is vulnerable to vascular risk factors in men:Apopulation-Based study. Eur J Neurol 19, 876-883.
87. Chui HC, Zheng L, Reed BR, Vinters HV, Mack WJ (2012) Vascular risk factors and alzheimer's disease: Are these risk factors for plaques and tangles or for concomitant vascular pathology that increases the likelihood of dementia? An evidence-Based review. Alzheimers Res Ther 3, 36.
88. Hoffman LB, Schmeidler J, Lesser GT, Beeri MS, Purohit DP, Grossman HT, Haroutunian V (2009) Less alzheimer disease neuropathology in medicated hypertensive than nonhypertensive persons. Neurology 72, 1720-1726.
89. Arvanitakis Z, Schneider JA,Wilson RS, Bienias JL,Kelly JF, Evans DA, Bennett DA (2008) Statins, incident alzheimer disease, change in cognitive function, and neuropathology. Neurology 70, 1795-1802. (Pubitemid 351653958)
90. Sonnen JA, Larson EB, Walker RL, Haneuse S, Crane PK, Gray SL, Breitner JC, Montine TJ (2010) Nonsteroidal antiinflammatory drugs are associated with increased neuritic plaques. Neurology 75, 1203-1210.
91. Fratiglioni L, Qiu C (2011) Prevention of cognitive decline in ageing: Dementia as the target, delayed onset as the goal. Lancet Neurol 10, 778-779.
92. de laTorre JC (2010)Vascular risk factor detection and control may prevent alzheimer's disease. Ageing Res Rev 9, 218-225.